• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Assertio Holdings Inc.

    11/10/25 4:07:00 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ASRT alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001722360
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    ASSERTIO HOLDINGS, INC.
    SEC File Number
    001-39294
    Address of Issuer
    100 South Saunders Road, Suite 300
    Lake Forest
    ILLINOIS
    60045
    Phone
    (224) 419-7106
    Name of Person for Whose Account the Securities are To Be Sold
    DAVID STARK
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Morgan Stanley Smith Barney LLC Executive Financial Services
    1 New York Plaza
    8th Floor
    New York � NY � 10004
    89596806.159623962511/10/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common11/07/2025Restricted StockIssuerCheckbox not checked895911/07/2025Not Applicable

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Date of Notice
    11/10/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    11/22/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ David Stark

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $ASRT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASRT

    DatePrice TargetRatingAnalyst
    7/26/2024$3.00Buy
    Maxim Group
    7/3/2024$4.00Buy
    H.C. Wainwright
    11/7/2022$7.00Buy
    Lake Street
    More analyst ratings

    $ASRT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on Assertio Therapeutics with a new price target

    Maxim Group initiated coverage of Assertio Therapeutics with a rating of Buy and set a new price target of $3.00

    7/26/24 7:49:44 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Assertio Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Assertio Therapeutics with a rating of Buy and set a new price target of $4.00

    7/3/24 7:25:55 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lake Street initiated coverage on Assertio Therapeutics with a new price target

    Lake Street initiated coverage of Assertio Therapeutics with a rating of Buy and set a new price target of $7.00

    11/7/22 9:24:08 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASRT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Assertio Announces Leadership Transition

    Appoints Industry Veteran and Current Director Mark L. Reisenauer as CEO, Effective Immediately Company Will Report Third Quarter Results on November 10, 2025 and Expects to Update Guidance Within the Current Range at That Time LAKE FOREST, Ill., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), today announced that its Board of Directors (the "Board") has appointed director Mark L. Reisenauer as the Company's Chief Executive Officer ("CEO"), effective immediately. As part of this transition, current CEO Brendan P. O'Grady will be departing the Company. Heather L. Mason, Chair of the Board of Directors, stated, "After significant del

    10/28/25 9:15:00 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Assertio Presents First-Ever Real-World Study Showing Patient Experience with SYMPAZAN® (clobazam) Oral Film, CIV

    New data show how Sympazan is being used in daily clinical practice to treat patients with Lennox-Gastaut Syndrome (LGS), a severe form of childhood-onset epilepsyStudy addresses lack of awareness and real-world data with oral film formulation of clobazamNew data presented during poster session at 150th Annual Meeting of the American Neurological AssociationSYMPAZAN is the only FDA-approved oral film formulation of clobazam for adjunctive treatment of seizures associated with LGS in patients two years of age or older BALTIMORE, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a pharmaceutical company with comprehensive commercial

    9/15/25 9:00:00 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Assertio to Present New Data from Real-World Evidence Study of SYMPAZAN® at upcoming 150th Annual Meeting of the American Neurological Association

    Poster presentation will feature new data for SYMPAZAN, the only FDA-approved oral film formulation of clobazam for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients two years of age or olderAbstract is now available on ANA2025 website LAKE FOREST, Ill., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to address patients' needs, today announced that the company will present new data for SYMPAZAN (clobazam) Oral Film in a poster presentation at the 150th Annual Meeting of the American Neurolo

    9/10/25 7:30:14 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASRT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO O'Grady Brendan P. converted options into 166,665 shares and covered exercise/tax liability with 49,416 shares, increasing direct ownership by 1,002% to 128,955 units (SEC Form 4)

    4 - Assertio Holdings, Inc. (0001808665) (Issuer)

    6/3/25 6:00:13 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, General Counsel Schlessinger Sam converted options into 38,017 shares and covered exercise/tax liability with 14,958 shares, increasing direct ownership by 15% to 176,948 units (SEC Form 4)

    4 - Assertio Holdings, Inc. (0001808665) (Issuer)

    5/14/25 6:03:08 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Schwichtenberg Paul converted options into 38,017 shares and covered exercise/tax liability with 16,840 shares, increasing direct ownership by 14% to 167,522 units (SEC Form 4)

    4 - Assertio Holdings, Inc. (0001808665) (Issuer)

    5/14/25 6:01:08 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASRT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mason Heather L bought $60,000 worth of shares (75,000 units at $0.80), increasing direct ownership by 35% to 287,650 units (SEC Form 4)

    4 - Assertio Holdings, Inc. (0001808665) (Issuer)

    11/19/24 9:02:18 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO O'Grady Brendan P. bought $9,950 worth of shares (11,706 units at $0.85) (SEC Form 4)

    4 - Assertio Holdings, Inc. (0001808665) (Issuer)

    11/15/24 2:43:25 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Vacirca Jeff L bought $11,100 worth of shares (10,000 units at $1.11), increasing direct ownership by 7% to 151,159 units (SEC Form 4)

    4 - Assertio Holdings, Inc. (0001808665) (Issuer)

    6/12/24 6:00:09 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASRT
    SEC Filings

    View All

    SEC Form 10-Q filed by Assertio Holdings Inc.

    10-Q - Assertio Holdings, Inc. (0001808665) (Filer)

    11/10/25 4:57:25 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Assertio Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits

    8-K - Assertio Holdings, Inc. (0001808665) (Filer)

    11/10/25 4:13:04 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Assertio Holdings Inc.

    144 - Assertio Holdings, Inc. (0001808665) (Subject)

    11/10/25 4:07:00 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASRT
    Financials

    Live finance-specific insights

    View All

    Assertio Announces Leadership Transition

    Appoints Industry Veteran and Current Director Mark L. Reisenauer as CEO, Effective Immediately Company Will Report Third Quarter Results on November 10, 2025 and Expects to Update Guidance Within the Current Range at That Time LAKE FOREST, Ill., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), today announced that its Board of Directors (the "Board") has appointed director Mark L. Reisenauer as the Company's Chief Executive Officer ("CEO"), effective immediately. As part of this transition, current CEO Brendan P. O'Grady will be departing the Company. Heather L. Mason, Chair of the Board of Directors, stated, "After significant del

    10/28/25 9:15:00 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Assertio Holdings, Inc. to Report Second Quarter 2025 Financial Results on August 11, 2025

    LAKE FOREST, Ill., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT) today announced that it will release second quarter 2025 financial results on Monday, August 11, 2025, after the market close. Additionally, Assertio's management will host a live webcast conference call at 4:30 p.m. Eastern Time to discuss the financial results and provide business updates on the Company's 2025 strategic plans. To access the live webcast, conference call information, and other materials, please visit Assertio's investor relations website at http://investor.assertiotx.com/overview/default.aspx. Please connect at least 10 minutes prior to the live webcas

    8/5/25 8:30:00 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Assertio Holdings, Inc. to Report First Quarter 2025 Financial Results on May 12, 2025

    LAKE FOREST, Ill., May 05, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT) today announced that it will release first quarter 2025 financial results on Monday, May 12, 2025, after the market close. Additionally, Assertio's management will host a live webcast conference call at 4:30 p.m. Eastern Time to discuss the financial results and update the Company's 2025 strategic plans. To access the live webcast, conference call information, and other materials, please visit Assertio's investor relations website at http://investor.assertiotx.com/overview/default.aspx. Please connect at least 10 minutes prior to the live webcast to ensure adequate tim

    5/5/25 8:15:00 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASRT
    Leadership Updates

    Live Leadership Updates

    View All

    Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors

    LAKE FOREST, Ill., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced today that Mark Reisenauer has been appointed as an independent director to the Company's Board of Directors. Mr. Reisenauer will serve as a member of the Compensation Committee. "Mark is a highly accomplished commercial leader in complex, competitive therapeutic areas who also brings extensive oncology and hematology product experience to our board," said Heather Mason, Chair of Assertio. "His successful new product and indication launches have b

    12/17/24 8:30:00 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Assertio Holdings, Inc. Appoints Paul Schwichtenberg to New CTO Role, Mary Pietryga as CCO

    LAKE FOREST, Ill., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced today the creation of a new Transformation Office and the appointment of Paul Schwichtenberg as Chief Transformation Officer (CTO). Mr. Schwichtenberg currently serves as the company's Chief Commercial Officer and was previously CFO. "As CTO, Paul will be future looking, working closely with me, to identify synergies, innovative strategies, and new revenue streams to best position the company for future growth," said Brendan O'Grady, Chief Executi

    12/12/24 8:00:00 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

    CAMBRIDGE, Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Sravan K. Emany as chief financial officer (CFO), effective December 19, 2024. Mr. Emany brings to Beam a breadth of global operational, commercial and financial experience with multinational public corporations and financial institutions. He most recently served as CFO and chief operating officer at Ironwood Pharmaceuticals, Inc. "Beam has built a strong financial position to advance our portfolio of genetic medicines, and Sravan has an exceptional background to lead our capital fo

    12/6/24 7:00:00 AM ET
    $ASRT
    $BEAM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $ASRT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Assertio Holdings Inc.

    SC 13G/A - Assertio Holdings, Inc. (0001808665) (Subject)

    11/14/24 3:52:50 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Assertio Holdings Inc.

    SC 13G/A - Assertio Holdings, Inc. (0001808665) (Subject)

    11/12/24 1:34:28 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Assertio Holdings Inc.

    SC 13G/A - Assertio Holdings, Inc. (0001808665) (Subject)

    11/4/24 11:29:13 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASRT
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at Assertio Holdings Inc. on Jun 6

    Recent insider transactions at Assertio Holdings Inc. have brought attention to the company's stock activity. On June 6, 2024, Mason Heather L purchased $24,250 worth of shares, acquiring 25,000 units at $0.97 per share. This transaction increased Mason Heather L's direct ownership by 13% to 212,650 units, as reported in the SEC Form 4. Several other notable insider transactions have taken place at Assertio Holdings Inc. leading up to this purchase. Patel Ajay, Schwichtenberg Paul, and Schlessinger Sam all converted options into shares and covered exercise/tax liability by utilizing their shares. These transactions resulted in ownership increases of 16%, 20%, and 21%, respectively. Addition

    6/10/24 1:20:50 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care